TABLE 1.

Drug susceptibilities for recombinant HIV with site-directed mutations

DrugEC50 (μM)a
HXB2D (wild type)K65RK65RM184V
Tenofovir3.1 ± 0.149.8 ± 1.2b (3.2)c6.3 ± 0.94b (2.0)
ddI4.3 ± 0.4115.4 ± 2.7b (3.6)29.5 ± 1.77b (6.9)
Abacavir0.3 ± 0.021.1 ± 0.2b (3.8)15.0 ± 0.001b (52.0)
DXG1.9 ± 1.810.2 ± 2.2b (5.4)8.0 ± 1.2b (4.2)
AZT0.14 ± 0.020.07 ± 0.01 (0.5)0.06 ± 0.01 (0.4)
d4T7.5 ± 2.213.2 ± 2.5b (1.8)10.4 ± 1.6d (1.4)
  • a EC50 for recombinant viruses were determined by an XTT-based viability assay with MT-2 cells, and averages ± standard errors for three to eight experiments are shown.

  • b P < 0.001 compared to the EC50 for the wild-type by two-tailed Student's t test.

  • c The values in parentheses are the fold change in the EC50 for the mutant compared to that for the wild type.

  • d P < 0.05 compared to the EC50 for the wild type by two-tailed Student's t test.